These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23519541)

  • 21. Agomelatine-induced gynaecomastia.
    Tan HL
    Aust N Z J Psychiatry; 2013 Dec; 47(12):1211-2. PubMed ID: 23881078
    [No Abstract]   [Full Text] [Related]  

  • 22. Agomelatine: a novel atypical antidepressant.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2007 Dec; 45(12):13-7. PubMed ID: 18246859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerability of agomelatine: focus on hepatotoxicity.
    Gahr M; Kratzer W; Fuchs M; Connemann BJ
    Curr Drug Metab; 2014; 15(7):694-702. PubMed ID: 25255870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre.
    Gahr M; Zeiss R; Lang D; Connemann BJ; Schönfeldt-Lecuona C
    J Clin Pharmacol; 2015 Jul; 55(7):768-73. PubMed ID: 25650773
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients.
    Perlemuter G; Cacoub P; Valla D; Guyader D; Saba B; Batailler C; Moore K
    CNS Drugs; 2016 Sep; 30(9):877-88. PubMed ID: 27342740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of depression and melatonergic antidepressant treatment alone and in combination with sedative-hypnotics on heart rate variability: Implications for cardiovascular risk.
    Chang CC; Tzeng NS; Yeh CB; Kuo TBJ; Huang SY; Chang HA
    World J Biol Psychiatry; 2018 Aug; 19(5):368-378. PubMed ID: 28281386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Agomelatine: a review of adverse effects.
    Prescrire Int; 2013 Mar; 22(136):70-1. PubMed ID: 23593692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder.
    Lam RW
    Int Clin Psychopharmacol; 2007 Oct; 22 Suppl 2():S21-5. PubMed ID: 17917563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Agomelatine].
    Tessmer M
    Med Monatsschr Pharm; 2009 Aug; 32(8):282-8. PubMed ID: 19777735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agomelatine reduces craving in benzodiazepine addicts: a follow-up examination of three patients.
    Müller H; Seifert F; Maler JM; Kornhuber J; Sperling W
    Singapore Med J; 2012 Nov; 53(11):e228-30. PubMed ID: 23192510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Agomelatine-Related Shift to Mania in a Patient With Recurrent Depressive Disorder.
    Kennel J; Baus C; Dogui R; Siebert S; Riemenschneider M
    Prim Care Companion CNS Disord; 2017 Oct; 19(5):. PubMed ID: 29099551
    [No Abstract]   [Full Text] [Related]  

  • 32. Publication bias and outcome reporting bias: agomelatine as a case example.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2011 Sep; 49(9):11-4. PubMed ID: 21846075
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Agomelatine and Transient Elevation of Creatine Phosphokinase.
    Zormann A; Blum J; Suenderhauf C; Vogel M; Walter A
    Drug Res (Stuttg); 2016 Nov; 66(11):614-616. PubMed ID: 27504868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [QTc prolongation during treatment with agomelatine].
    Kozian R; Syrbe G
    Psychiatr Prax; 2010 Nov; 37(8):405-7. PubMed ID: 20848378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study.
    Stein DJ; Ahokas A; Albarran C; Olivier V; Allgulander C
    J Clin Psychiatry; 2012 Jul; 73(7):1002-8. PubMed ID: 22901350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Agomelatine: an antidepressant with new potent hepatoprotective effects on paracetamol-induced liver damage in rats.
    Karakus E; Halici Z; Albayrak A; Polat B; Bayir Y; Kiki I; Cadirci E; Topcu A; Aksak S
    Hum Exp Toxicol; 2013 Aug; 32(8):846-57. PubMed ID: 23584358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
    Kennedy SH; Rizvi S; Fulton K; Rasmussen J
    J Clin Psychopharmacol; 2008 Jun; 28(3):329-33. PubMed ID: 18480691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
    Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
    CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Agomelatine for depression: expanding the horizons?
    Norman TR; Olver JS
    Expert Opin Pharmacother; 2019 Apr; 20(6):647-656. PubMed ID: 30759026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.